INC.

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

by

New York, May 26, 2023 /PRNewswire/ — Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering what may be the first comprehensive salt and polymorph screens of the empathogens MDMA, (R)-MDMA, (S)-MDMA, MDEA (MDE), (S)-MDEA, (R)-MDEA, … Read more

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

by

SOUTH SAN FRANCISCO, Calif., May 26, 2023 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 25, 2023, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of … Read more

eMolecules acquires Specs Compound Handling B.V.

by

Combination expands footprint offering a global one-stop shop for streamlined chemical compound procurement and management services for drug discovery chemistry researchers. SAN DIEGO and ZOETERMEER, The Netherlands, May 25, 2023 /PRNewswire/ — eMolecules, Inc., an industry leading chemical compound search-and-fulfillment platform for early discovery chemistry research, today announced the acquisition of Specs Compound Handling B.V. … Read more

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

by

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patients CAMBRIDGE, Mass., May 25, 2023 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology … Read more

Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue

by

Aligning Management Team given New Refined Commercial Focus on Institutions Starting with Recent Appointment of Board Member Zhenya Lindgardt as Interim President and CEO Engages Leading Strategy House to Evaluate Best Pathways Toward Targeting Enhanced Revenue Generation at Significantly Reduced Operating Costs Nadia Altomare Expected to Move from Chief Commercial Officer to Consulting Role to … Read more

Hememics Biotechnologies, Inc. Announces Successful Close in $2 Million Seed 2 Financing from TEDCO and Qualified Investors to Accelerate Growth

by

GAITHERSBURG, Md., May 25, 2023 /PRNewswire/ — Hememics Biotechnologies, Inc., developer of first-in-class, handheld, multiplexed biosensor platform that can test antibodies, antigens and molecular targets simultaneously, announced today the closing of a $2 million Seed 2 financing round. Participants of this round include a strategic investor, existing investors and Maryland Technology Development Corporation (TEDCO). “I … Read more

PetSmart Charities to Name Endowed Chair at UC Davis School of Veterinary Medicine with $6 Million Gift

by

National nonprofit makes this and other investments in higher education to bolster access to veterinary care PHOENIX, May 25, 2023 /PRNewswire/ — PetSmart Charities® will name an endowed chair at the University of California, Davis, School of Veterinary Medicine for $6 million. The landmark partnership marks the largest gift to date made by the top … Read more

Nanomedicine Market to be Worth $410.15 Billion by 2030: Grand View Research, Inc.

by

SAN FRANCISCO, May 25, 2023 /PRNewswire/ — The global nanomedicine market size is expected to reach USD 410.15 billion by 2030, expanding at 11.57% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. The advantages of nanomedicine in numerous healthcare applications, the emergence of novel drug delivery technologies, and … Read more

111 to Announce First Quarter 2023 Unaudited Financial Results on June 15, 2023

by

SHANGHAI, May 25, 2023 /PRNewswire/ — 111, Inc. (NASDAQ: YI) (“111” or the “Company”), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2023, before the U.S. market opens … Read more

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®

by

SAN DIEGO, May 24, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial-stage oncology company, today announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis. SAPPHIRE is a Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 versus docetaxel in patients with second or third … Read more